Home > Journals > Minerva Obstetrics and Gynecology > Past Issues > Minerva Ginecologica 1999 December;51(12) > Minerva Ginecologica 1999 December;51(12):463-70

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions
Share

 

ORIGINAL ARTICLES   

Minerva Ginecologica 1999 December;51(12):463-70

Copyright © 1999 EDIZIONI MINERVA MEDICA

language: Italian

Expression and prognostic value of drug resistance-associated markers P-gp, Mrp1, Mrp2 and Lrp in ovarian cancer

Katsaros D., Fracchioli S., Arts H. J. G., de Vries E. G. E., Danese S., Richiardi G., Arisio R., Gordini G., Van der Zee A. G. J., Suurmeijer A. J. H., Massobrio M.


PDF


Background. Intrinsic and/or acquired chemoresistance is the major obstacle to overcome in the treatment of patients with ovarian carcinoma. The aim of the present study was to investigate the prognostic value of drug resistance associated proteins P-glycoprotein (P-gp), multidrug resistance related protein (Mrp1), canalicular multispecific organic anion trans-porter (c-MOAT or Mrp2) and lung resistance protein (Lrp) in ovarian carcinoma.
Methods. Expression of P-gp, Mrp1, Mrp2 and Lrp was determined by immunohistochemistry of frozen tissue sections of 115 ovarian carcinoma patients and associated to clinicopathological factors, response to chemotherapy and (progression free) survival.
Results. Expression of P-gp was observed in 20 out of 115 (17%), Mrp1 in 51 out of 115 (44%), Mrp2 in 19 out of 115 (16%) and Lrp in 85 out 115 (74%) tumors. Expression of Mrp1 was related to Mrp2 (p<0.0001) and P-gp (p<0.001) expression, while Lrp expression was more frequently observed in patients with stage I/II versus stage III/IV tumors (p<0.01), grade I/II versus III tumors (p<0.05) and residual tumor <2 cm versus >2 cm after laparotomy (p<0.05). Lower stage (p<0.001), small residual tumor after first laparotomy (p<0.001) and lower differentiation grade (p<0.05) were related to longer (progression free) survival. P-gp, Mrp1, Mrp2, and Lrp expression was neither related to response to first line chemotherapy (59 evaluable patients) nor to (progression free) survival (all patients). On multivariate analysis only stage and residual tumor after first laparotomy were independent prognostic factors for (progression free) survival.
Conclusions. In ovarian carcinoma Mrp1 expression is associated with Mrp2 and P-gp expression, while Lrp expression is associated with favorable clinicopathological characteristics. Assessment of P-gp, Mrp1, Mrp2 or Lrp does not allow prediction of response to chemotherapy or (progression free) survival in ovarian carcinoma.

top of page